Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
Jian Huang(Second Affiliated Hospital of Zhejiang University), Weiping Zhou(Second Military Medical University), Shengxian Yuan(Second Military Medical University), Ze‐Ya Pan(Second Military Medical University), Fangming Gu(Second Military Medical University), Wan Yee Lau(Chinese University of Hong Kong), Qi-fei Tao, Yun Yang(Second Military Medical University), Bei‐Ge Jiang(Second Military Medical University), Zhenguang Wang(Beijing Institute of Technology), Hui Liu(Second Military Medical University)
Cited by 6
Related Papers
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2005|591
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
|PubMed|1999|519
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
|PLoS ONE|2015|360